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A B S T R A C T
Background
Rimonabant is a selective type 1 cannabinoid (CB1) receptor antagonist. It may assist with smoking cessation by restoring the balance
of the endocannabinoid system, which can be disrupted by prolonged use of nicotine. Rimonabant also seeks to address many smokers’
reluctance to persist with a quit attempt because of concerns about weight gain.
Objectives
• To determine whether selective CB1 receptor antagonists increase the numbers of people stopping smoking
• To assess their effects on weight change in successful quitters and in those who try to quit but fail.
Search strategy
We searched the Cochrane Tobacco Addiction Review Group specialized register for trials, using the terms ’rimonabant’ and ’smoking’
in the title or abstract, or as keywords. We also searched MEDLINE, EMBASE, CINAHL and PsycINFO, using major MESH terms.
We acquired electronic or paper copies of posters of preliminary trial results presented at the American Thoracic Society Meeting in
2005, and at the Society for Research on Nicotine and Tobacco European Meeting 2006. We also attempted to contact the authors of
ongoing studies of rimonabant, and Sanofi Aventis (manufacturers of rimonabant).
Selection criteria
Types of studies
Randomized controlled trials
Types of participants
Adult smokers
Types of interventions
Selective CB1 receptor antagonists, such as rimonabant.
Types of outcome measures
The primary outcome is smoking status at a minimum of six months after the start of treatment. We preferred sustained cessation rates
to point prevalence, and biochemically verified cessation to self-reported quitting. We regarded smokers who drop out or are lost to
follow up as continuing smokers. We have noted any adverse effects of treatment.
A secondary outcome is weight change associated with the cessation attempt.
Data collection and analysis
Two authors checked the abstracts for relevance, and attempted to acquire full trial reports. One author extracted the data, and a second
author checked them.
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Main results
We found three trials which met our inclusion criteria, covering 1567 smokers (cessation: STRATUS-EU and STRATUS-US), and
1661 quitters (relapse prevention: STRATUS-WW). At one year, the pooled odds ratio (OR) for quitting with rimonabant 20 mg was
1.61 (95% confidence interval (CI) 1.12 to 2.30). No significant benefit was demonstrated for rimonabant at 5 mg dosage. Adverse
events included nausea and upper respiratory tract infections.
In the relapse prevention trial, smokers who had quit on the 20 mg regimen were 1½ times more likely to remain abstinent on either
active regimen than on placebo; theOR for the 20mgmaintenance group was 1.49 (95%CI 1.09 to 2.04, and for the 5mgmaintenance
group 1.51 (95% CI 1.11 to 2.07). There appeared to be no significant benefit of maintenance treatment for the 5 mg quitters.
Weight gain was reported to be significantly lower among the 20 mg quitters than in the 5 mg or placebo quitters. During treatment,
overweight or obese smokers tended to lose weight, while normal weight smokers did not.
Authors’ conclusions
• From the preliminary trial reports available, rimonabant 20 mg may increase the odds of quitting approximately 1½-fold.
• Adverse events include nausea and upper respiratory tract infections; the risk of serious adverse events is reported to be low.
• The evidence for rimonabant in maintaining abstinence is inconclusive.
• Rimonabant 20 mg may moderate weight gain in the long term.
P L A I N L A N G U A G E S U M M A R Y
Rimonabant is a selective CB1 receptor antagonist which may help smokers to quit, and may also reduce the amount of weight gained
during the quitting process
Long-term use of nicotine can upset the endocannabinoid system in the brain, which controls food intake and energy balance.
Rimonabant may help smokers to quit by rebalancing the system, which then reduces nicotine and food cravings. We searched our
own specialised register of controlled trials. We also contacted Sanofi-Aventis, the manufacturers of rimonabant, and researchers who
presented early findings at conferences. We found two randomized controlled trials (RCTs) of rimonabant for smoking cessation,
covering 1567 smokers, and one RCT of rimonabant for relapse prevention covering 1661 quitters. Although full trial reports are not
yet published, our own analyses show that rimonabant at the 20 mg dose increased by 1½-fold the odds of not smoking at one year,
compared with placebo. Rimonabant 5 mg did no better than placebo at any time point. In the relapse prevention trial, smokers who
quit successfully on rimonabant 20 mg were 1½ times more likely to remain abstinent on active treatment (5 mg or 20 mg) than on
placebo. For those who quit successfully on 5 mg, neither active nor placebo treatment appeared to benefit them in avoiding relapse.
This inconsistent picture makes it difficult to find a clear benefit for rimonabant in preventing relapse. Although the evidence on weight
change is sparse in these trials, weight gain was reported to be significantly lower among the 20 mg quitters than in the 5 mg or placebo
quitters. During treatment, overweight or obese smokers tended to lose weight on 20 mg, while normal weight smokers did not. Main
side effects were nausea and upper respiratory tract infections, and serious harms were reported to be low.
B A C K G R O U N D
About 70% of smokers want to quit, with the majority citing con-
cerns about their health as a primary reason for giving up smok-
ing (ONS 2002). There is widespread concern among smokers,
however, about the risks of gaining weight after quitting. In the
USA it is estimated that 75% of smokers gain weight when they
stop smoking (USPHS 1990), with the majority of the weight
gain in the first year of smoking abstinence (O’Hara 1998). Men
who sustain abstinence have been shown to gain an average of
4.9 kilograms in the first year of abstinence, and women 5.2 kilo-
grams, with further gains of 2.7 kilograms and 3.5 kilograms re-
spectively across the following four years of abstinence (O’Hara
1998).Other evidence suggests that in the longer term ex-smokers’
weight may return to the comparable weight of someone who has
never smoked (Mizoue 1998). While some studies have suggested
that nicotine replacement therapy or bupropion may moderate
post-cessation weight gain (Filozof 2004), no pharmacotherapies
are yet available that target both smoking cessation and weight
control simultaneously.
The central cannabinoid (CB1) receptors have recently been im-
plicated in brain reward function, and are thought to have a role
in controlling food consumption and in dependence and habit-
uation. Excessive eating and fat accumulation are associated with
over-activation of the endocannabinoid system, which is involved
in the regulation of food intake and energy expenditure. Repeated
nicotine use may also overstimulate the endocannabinoid system.
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It is thought that rimonabant may work by selectively blocking
the CB1 receptors,thereby restoring the balance and inhibiting
nicotine and food cravings.
Rimonabant (SR 141716; trade name Acomplia) is the first se-
lective cannabinoid type 1 receptor antagonist to have been pro-
duced and clinically tested. It was developed initially as a possible
treatment for obesity, but it has also been proposed as an aid to
smoking cessation andmay have the potential to protect successful
quitters from significant post-cessation weight gain (ACC 2004;
Sanofi-Synth 2004). The development and testing of rimonabant
is of particular interest to clinicians, as it may offer an effective and
simultaneous treatment for the two major cardiac risk factors of
obesity and smoking. Moreover, smoking cessation is itself associ-
ated with weight gain. Rimonabant therefore also seeks to address
many smokers’ reluctance to persist with a quit attempt because
of concerns over weight gain (Pomerleau 2000). The beneficial
effects of rimonabant on weight loss have been demonstrated in a
recent Cochrane review (Curioni 2006).
Rimonabant 20 mg dose has been licensed for use for weight con-
trol in the European Union since June 2006, but has not been
licensed as a smoking cessation aid. It has not yet been approved
by the FDA for sale in the USA. The Summary of Product Char-
acteristics (Acomplia SPC 2006) advises against its use by those
with severe hepatic or renal impairment, severe psychiatric illness
or lactose intolerance, and advises caution in its use by the elderly,
by patients with epilepsy or by those on antidepressant treatment.
It is also contra-indicated during pregnancy or while breast-feed-
ing.
Phase III trials have been conducted to test the use of rimonabant
for long-term smoking cessation with the avoidance of significant
weight gain. The STRATUS program (STudies with Rimonabant
And Tobacco USe), has produced conference reports of two ces-
sation trials (STRATUS-EU 2006 and STRATUS-US 2006), and
has reported intermediate outcomes for a two-year relapse preven-
tion trial (STRATUS-WW 2005).
O B J E C T I V E S
1. To determine whether selective CB1 receptor antagonists in-
crease the numbers of people stopping smoking.
2. To assess their effects on weight change in successful quitters
and in those who try to quit but fail.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Randomized controlled trials
Types of participants
Adult smokers
Types of intervention
Selective CB1 receptor antagonists, such as rimonabant, and any
other drugs of this class as they reach Phase II or Phase III trial stage.
The drugs may be used alone or in combination with behavioural
therapies or other pharmacotherapies.
Types of outcome measures
The primary outcome is smoking status at a minimum of six
months after the start of treatment. Trials with shorter follow
up have not been included in the meta-analysis. We have used
sustained cessation rates in preference to point prevalence; sus-
tained cessation refers either to complete abstinence (continuous)
or to prolonged abstinence (complete abstinence following a post-
quit two-week period of grace in which minor relapse may occur)
(Hughes 2003). We prefer biochemically verified cessation to self-
reported quitting. The strictest definition of smoking cessation
reported was used in the meta-analysis. Types of abstinence (con-
tinuous, prolonged, point prevalence) and levels of verification
(biochemical, self-report) have been considered as potential mod-
erators of outcome. We regard smokers who drop out or are lost
to follow up as continuing smokers. We have noted any adverse
effects of treatment.
A secondary outcome is change inweight associatedwith the cessa-
tion attempt.We have assessed change in baseline weight at longest
follow up (currently one year), and at the end of pharmacotherapy.
We have considered weight change in the subgroup of successful
quitters, in all those who were randomized, in the subgroup of
those who have failed to quit, according to weight classification
at baseline, and in the total sample, testing the sensitivity of the
results to different ways of handling missing data.
The possible findings include:
(i) Selective CB1 receptor antagonists may increase smoking ab-
stinence rates relative to a control or non-intervention group, and
there may be a significantly larger average weight gain in the in-
tervention than in the control group. Interpretation: The weight
gain in the intervention group would most probably be due to the
higher number of quitters in this group and there would be no
evidence to suggest that the intervention has reduced weight gain.
(ii) Selective CB1 receptor antagonists may increase quit rates rel-
ative to a control or non-intervention group, but without a signif-
icant difference in average weight gain between the groups. Inter-
pretation: This result would be difficult to interpret. It is possible
that the intervention may have counteracted some of the antici-
pated weight gain among the quitters. However, it is also possible
that there was a similar weight gain in quitters and continuing
smokers independently of the effects of the intervention.
(iii) Selective CB1 receptor antagonists may increase quit rates
relative to a control or non-intervention group, and there may
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be a significantly smaller average weight gain in the intervention
group than in the control group. Interpretation: This would be
good evidence to suggest that the intervention has reduced weight
gain.
(iv) There may be no difference in quit rates between the selective
CB1 receptor antagonists group and the control group, but a sig-
nificantly smaller average weight gain in the intervention group
than in the control group. Interpretation: This would be evidence
for selective CB1 receptor antagonists counteracting weight gain.
Since selectiveCB1 receptor antagonistsmay have beneficial effects
on other risk factors for the development of cardiovascular disease
(Cleland 2004) these outcomes have also been considered.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Tobacco Addiction Group methods used in
reviews.
We searched the Cochrane Tobacco Addiction Review Group
specialized register for trials, using the terms ’rimonabant’ and
’smoking’ in the title or abstract, or as keywords. This register
has been developed from electronic searching of MEDLINE,
EMBASE, Science Citation Index and PsycINFO, together with
handsearching of specialist journals, conference proceedings
and reference lists of previous trials and overviews. We have
also searched MEDLINE, EMBASE, and PsycINFO, using the
major MESH terms (Endocannabinoids-physiology, Receptors,-
cannabinoid-agonists or Receptors,-cannabinoid-antagonists-
and-inhibitors) or equivalent for other databases, combined with
MeSH or free text smoking-related terms (smok* or tobacco or
cigar* or nicotine). We have acquired electronic and/or paper
copies of posters of preliminary trial results presented at the
American Thoracic Society Meeting in 2005, and at the Society
for Research on Nicotine and Tobacco European Meeting 2006.
We have also attempted to contact the authors of ongoing
studies of rimonabant, and Sanofi Aventis (manufacturers of
rimonabant).
M E T H O D S O F T H E R E V I E W
Two authors checked the abstracts of studies generated by the
search strategy for relevance, and attempted to acquire full reports
of any trials that might be included in the review, but with only
limited success.One author extracted the data, and a second author
checked them. Any discrepancies were resolved bymutual consent,
or by recourse to the editorial base. We have noted reasons for the
non-inclusion of studies.
DATA EXTRACTION
The following information, where it was available for each trial, is
reported in the Table ’Characteristics of Included Studies’:
• Country and setting (e.g. primary care, community, hospital
outpatient/inpatient).
• Method of selection of participants (e.g. willingness to make a
quit attempt).
• Definition of smoker used.
• Method of randomization, and blinding of trialists, participants
and assessors.
• Demographic characteristics of participants (e.g. average age,
sex, average cigs/day).
• Intervention and control description (provider, length of
treatment, number of visits, etc.).
• Outcomes including definition of abstinence used, and
biochemical validation of cessation.
• Proportion of participants with follow-up data.
• Any adverse events.
• Secondary outcomes, includingweight changes during and after
cessation, and other outcomes relevant to cardiovascular risk,
including lipid levels.
EVALUATION OF QUALITY
We evaluated the studies on the basis of the quality of the
randomization and allocation concealment procedure used, as
described in the Cochrane Handbook. Studies are scored A
if a method of randomization and allocation concealment are
reported that minimize the chance of selection bias. If insufficient
information is available they are scored B, and studies where
allocation was not concealed at the point of enrolment are scored
C.
We calculated quit rates based on the numbers of patients
randomized to an intervention, and excluding any deaths. We
have used an intention-to-treat (ITT) analysis, i.e. including
all randomized participants in the groups to which they were
originally assigned. We have regarded those who drop out or are
lost to follow up as continuing smokers. We have noted any deaths
and adverse events in the Results section.
WEIGHT CHANGE
For assessing the impact on weight change we have considered the
following outcomes where reported:
• Mean change in weight from baseline (pre-cessation) for
confirmed quitters. Since quitting is likely to be associated
with weight gain, an examination of the subgroup of successful
quitters will provide the most sensitive test of the impact of
selective CB1 receptor antagonists on weight gain.
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• Mean weight change from baseline in point prevalence
quitters compared with quitters with continuous or prolonged
abstinence.
• Mean change in weight from baseline for those failing to
quit smoking. This outcome allows an assessment of whether
selective CB1 receptor antagonists affect changes in weight
among those who relapse or who continue to smoke.
• Mean change in weight from baseline for those completing the
study.
• Mean change in weight for those sub-groups who are classed as
obese, overweight or normal weight at baseline.
• Mean change in weight from baseline, using an intention-to-
treat (ITT) analysis, with lastweightmeasure carried forward for
study dropouts and losses to follow up. Some of the findings by
ITTmay be difficult to interpret as quitting is of itself associated
with weight gain.
We have considered weight change at the end of pharmacotherapy
and at the longest follow up.
Other outcomes relevant to cardiovascular risk, for example lipid
levels, have been extracted if reported at long-term follow up.
Where appropriate, we have conducted a meta-analysis of the
included studies, using theMantel-Haenszel odds ratio and afixed-
effect model, provided that there was no significant heterogeneity.
We include in this review the Tobacco Addiction Group glossary
of tobacco-specific terms (Table 01).
D E S C R I P T I O N O F S T U D I E S
We identified three trials whichmet our inclusion criteria. All were
Phase III trials, funded and managed by the makers of rimona-
bant, Sanofi Aventis. Two trials of identical design (STRATUS-
EU 2006; STRATUS-US 2006) evaluated rimonabant for smok-
ing cessation, and one trial evaluated rimonabant as an aid to re-
lapse prevention (STRATUS-WW 2005).
The two cessation trials covered 1567 smokers, 1046 of whom
were on active treatment (20 mg or 5 mg). The relapse preven-
tion trial began with 5055 smokers, all of whom were on active
treatment. During the second phase the 1661 quitters were re-
randomized to a maintenence dose of active or placebo treatment
for a further 42 weeks. Full details of each trial are given in the
Table of Included Studies.
STRATUS-EU 2006 was a multi-centre study, set in seven Eu-
ropean countries (Sanofi 2003), while STRATUS-US 2006 was
conducted at a clinic in Pennsylvania. The relapse prevention trial
(STRATUS-WW2005)was set inCanada, Australia and theUSA.
All three trials tested rimonabant at dosage levels of 5 mg and
20 mg, and compared it with a placebo. For the cessation trials,
the treatment period was 10 weeks, with a target quit date set
for day 15, and follow up for an additional 40 weeks. In the
relapse prevention trial (STRATUS-WW 2005) participants who
achieved abstinence after 10 weeks of treatment on either a 5 mg
or a 20 mg regimen were then re-randomized to either 5 mg or
placebo (the 5 mg quitters) or to 5 mg, 20 mg or placebo (the 20
mgquitters) for a further 42weeks of relapse prevention treatment.
Successful abstainers at one year in this trial were then followed
for a further 52 weeks without treatment.
The cessation trials included brief behavioural counselling at
weekly visits throughout the treatment phase, covering cessation-
related topics such as craving and relapse prevention, and also
diet and exercise but without dietary restrictions. Brief counselling
continued at regular clinic visits throughout the follow-up phase.
The relapse prevention trial did not report on behavioural sup-
port.
The primary outcome for the cessation trials was continuous ab-
stinence through weeks 7 to 10 (end of treatment). Both trials also
reported the secondary outcome of continuous abstinence through
weeks 2 to 50, and also 7-day point prevalence abstinence at weeks
8, 10 and 50. Although cessation and/or relapse prevention were
the focus of the three trials, all of them also reported weight change
as a secondary outcome of interest. The relapse prevention trial
also reported on changes in HDL-cholesterol and in triglycerides.
M E T H O D O L O G I C A L Q U A L I T Y
None of the trials has yet reported their methods of randomization
or allocation concealment, and are therefore rated B (unclear) for
their attempts to control selection bias.
In our dependence upon preliminary unpublished reports, we
have sometimes found the data to be inconsistent across different
sources. The denominators for the STRATUS-EU groups shift
between sources and within the same source. We assume that the
published reports will present the definitive data.
All three trials defined their abstinence outcome as ’prolonged’
i.e. continuous after a post-quit date grace period of two weeks
(Hughes 2003), and biochemically verified at each visit by expired
carbon monoxide (CO) levels of 10 or fewer parts per million. In
the cessation trials, cotinine was also used to verify abstinence at
baseline, at weeks 8 and 10, and during the follow-up phase at
weeks 14, 32 and 50. The relapse prevention trial used exhaled
CO to verify abstinence during the 10-week cessation phase, and
has not reported its validation procedure for the relapse prevention
or the no-treatment phases.
Rates of non-completion of the treatment phase were around 30%
for STRATUS-US 2006, and around 40% for STRATUS-EU
2006, without significantly different losses between groups. Non-
completion rates for phases 1 and 2 have not been reported for the
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relapse prevention trial, and none of the trials has reported long-
term losses to follow up.
R E S U L T S
Cessation
Both trials (STRATUS-EU 2006; STRATUS-US 2006) detected
a benefit of rimonabant 20 mg over placebo for prolonged absti-
nence at 50 weeks, although the odds ratio (OR) for the STRA-
TUS-EU 2006 trial failed to reach statistical significance (1.31,
95% confidence interval [CI] 0.83 to 2.09). The pooled OR for
the two trials was 1.61 (95% CI 1.12 to 2.30; comparison 01.01).
The pooled OR for continuous abstinence at end of treatment (7
to 10 weeks) was similar, at 1.63 (95%CI 1.21 to 2.19; comparison
01.02). No significant benefit of rimonabant 5 mg over placebo
was demonstrated at either 50 weeks (OR 1.13, 95% CI 0.77 to
1.66; comparison 03.01) or at end of treatment (OR 1.15, 95%
CI 0.84 to 1.56; comparison 03.02).
We compared the effect of the two doses of rimonabant for pro-
longed abstinence at 50 weeks and at end of treatment across both
trials, and found a modest benefit of the 20 mg regimen over the 5
mg regimen: OR 1.42, 95%CI 1.00 to 2.02 at 50 weeks (compari-
son 04.01), andOR1.42, 95%CI 1.06 to 1.90 at end of treatment
(comparison 04.02).
Relapse prevention
At the end of the phase 1 10-week treatment regimen in STRA-
TUS-WW 2005, both the 5 mg and the 20 mg groups had similar
cessation rates of 31.8% and 33.6% respectively. Those 5mg quit-
ters who were then randomized to the same treatment for phase
2 did not differ significantly from the 5 mg/placebo quitters in
relapse rates at 52 weeks. The phase 1 20 mg quitters who were
then randomized to the two active treatment groups in phase 2
maintained significantly higher cessation rates than the placebo
group, with an OR for the 20/20 mg group of 1.49 (95% CI 1.09
to 2.04; comparison 02.01) and an OR for the 20/5 mg group of
1.51 (95% CI 1.11 to 2.07; comparison 02.02), compared with
placebo. Phase 2 participants were scheduled to be followed up for
a period of 104 weeks, but at present we have no results beyond
the 52-week outcomes described here.
Weight change
Findings for those maintaining abstinence from smoking:
Among participants maintaining smoking abstinence from 2 to
48 weeks after their quit date, a pooled analysis for STRATUS-EU
2006 and STRATUS-US 2006 shows that those on rimonabant
20 mg gained significantly less weight than those on 5 mg or
placebo (P < 0.05; STRATUS-EU 2006). There was no significant
difference for 5 mg versus placebo. Separate data for the American
and European trials were not presented. At the 52-week follow
up in STRATUS-WW 2005, among those avoiding relapse to
smoking post-cessation weight gain was significantly lower in the
rimonabant 20 mg group versus placebo (P < 0.001). Weight gain
was similar in the placebo and rimonabant 5 mg groups. The
extent of the weight gain in STRATUS-WW 2005 was shown
graphically, but not reported as absolute changes in kilos.
In a pooled analysis of STRATUS-US 2006 and STRATUS-EU
2006, among those remaining abstinent from smoking throughout
the final four weeks of treatment, those taking rimonabant 20 mg
gained significantly less weight than those on placebo (P < 0.001),
although it is unclear whether this was measured at ten or at 48
weeks. There were no significant differences when comparing 5
mg rimonabant with placebo. In STRATUS-EU 2006, among
non-obese participants, the rimonabant 20 mg users (N = 54) had
a mean weight gain of 0.5 kg; for rimonabant 5 mg (users N =
53) the gain was 1.6 kg; those on placebo (N = 44) gained 2.3
kg. Details of weight changes were not given for STRATUS-US
2006.
Findings using intention-to-treat (ITT) analysis:
When considering all those smokers who were randomized (ITT
analysis), in the STRATUS-US 2006 trial, on average across the
10-week treatment period, those on rimonabant 20 mg lost 0.3
kg, while those on placebo gained 1.1 kg (P < 0.001). Participants
who were overweight (body mass index [BMI: weight in kg/height
in m2] = 25 to 29.9) or obese (BMI = 30+) tended to lose weight
using rimonabant 20 mg, while normal-weight participants (BMI
=18.5 to 24.9) did not.Overweight smokers on rimonabant 20mg
lost 0.5 kg on average, versus a gain of 0.9 kg for those on placebo.
Obese smokers on rimonabant 20 mg lost 0.6 kg compared with
a gain of 1.3 kg for those on placebo. For those of normal weight
there was no weight change when using rimonabant 20 mg, but
those on placebo gained 1.0 kg.Only the finding for obese smokers
reached statistical significance (P < 0.001). Weight change for the
rimonabant 5 mg group was not reported.
Again using an ITT analysis, in STRATUS-EU 2006 those on ri-
monabant 20 mg (N = 267) lost 0.5 kg, while those on placebo (N
= 260) and 5 mg (N = 256) gained 1.0 kg and 0.2 kg respectively,
across the treatment period. In STRATUS-WW 2005, among all
re-randomized participants at the 52 week follow-up, those on ri-
monabant 20 mg (N=340), 5 mg (N=335) and placebo (N=342)
gained an average of 0.6 kg, 1.9 kg and 2.0 kg respectively. As with
STRATUS-US 2006, for STRATUS-EU 2006 and STRATUS-
WW 2005 the difference in weight gain for 20 mg versus placebo
reached statistical significance (P = 0.001, P < 0.001 respectively).
Where there were missing data, the ITT analysis for STRATUS-
EU 2006 and STRATUS-WW 2005 was based on ’last observa-
tion carried forward’. It is not clear whether this approach was also
used for the ITT analysis for STRATUS-US 2006.
Adverse events:
The three trials demonstrated disparate patterns of adverse events.
STRATUS-US 2006 reported nausea as the most frequent side ef-
fect, occurring in 15.7% of the 20 mg group compared with 9.2%
in the 5 mg group and 8.8% in the control group (differences
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not statistically significant). This paralleled the predominance and
rates of nausea as the main side effect reported in the RIO trials,
which tested rimonabant as a treatment for weight control (Curi-
oni 2006). Nausea was not mentioned as a significant side effect in
STRATUS-EU 2006, which listed fatigue, depressed mood, anx-
iety and nasopharyngitis as the most commonly reported events.
Upper respiratory tract infection was the most frequent adverse
event for the STRATUS-WW 2005 participants, at around 18%
across all groups, with nasopharyngitis as the nextmost commonly
reported event (mean 10.5% across all groups). Again, nausea was
not mentioned as a significant side effect for any group in this trial.
It should be noted, however, that the Summary of ProductCharac-
teristics (Acomplia SPC 2006) reports the incidence of nausea and
upper respiratory tract infections as ’very common’ (i.e. > 10%)
when rimonabant is used for weight control.
Drop-out rates attributable to adverse events were consistently
highest in the 20 mg groups and lowest in the control groups,
with only STRATUS-EU 2006 reporting a statistically signifi-
cantly higher drop-out rate in the 20 mg group (14.6%) com-
pared with the placebo group (6.9%; X2 8.22, P = 0.004). STRA-
TUS-EU 2006 reported significantly higher rates of drop-out at-
tributable to adverse events across all groups (placebo 6.9%, 5 mg
9.8%, 20 mg 14.6%) compared with STRATUS-US 2006 (3.8%,
5.7%, 6.9% respectively) and with STRATUS-WW 2005 (6.1%,
6.3%, 9.7% respectively). However, the STRATUS-EU 2006 at-
tributable drop-out rates were similar to those reported in the four
RIO trials (Curioni 2006).
Information on serious adverse events (SAEs) is sparse at present.
At one year follow up, STRATUS-WW 2005 reports SAE rates
of 5%, 3.6% and 5.3% in placebo, 5 mg and 20 mg groups re-
spectively. The corresponding figures for STRATUS-EU 2006 are
2.7%, 0.8%and 2.2%, i.e. the placebo group reporting the highest
rate, but with a statistically non-significant difference. STRATUS-
US 2006 has not reported separate group rates, but has confirmed
that no cardiovascular safety concerns were raised by their find-
ings. A pooled analysis of STRATUS-EU, STRATUS-META and
STRATUS-US reports SAEs running at 2% in the rimonabant 20
mg group compared with 2.2% in the placebo group (STRATUS
META 2006). This may be compared with SAE rates in the RIO
(rimonabant in obesity) trials, which ranged from 4% to 8%, with
a pooled relative risk increase of 1.37 (95% CI 1.04 to 1.80, P =
0.03) in the 20 mg groups compared with placebo groups (Curi-
oni 2006).
D I S C U S S I O N
Our review has suffered from a lack of peer-reviewed and pub-
lished study reports. Despite our best efforts to obtain informa-
tion, we have had to rely on conference presentations, press re-
leases and pharmaceutical company reports, and we are aware that
the findings of this review are tentative and incomplete. We look
forward to the eventual disclosure of methodological details, in-
cluding randomization and allocation procedures, exclusion cri-
teria, verification methods, and levels of behavioural support. We
also await full details of attrition rates, losses to follow up, indi-
vidual trial results and comprehensive long-term outcome data.
Furthermore, all the trials reviewed so far were sponsored by the
pharmaceutical company manufacturing rimonabant. Since con-
flicts of interest could influence the results, their findings should
be treated with caution.
Smoking cessation
The two cessation trials have detected a benefit of rimonabant 20
mg over placebo at longest reported follow up, with a statistically
significant pooled OR of 1.6. There was also a modest but signif-
icant benefit of the 20 mg dose over the 5 mg dose (pooled OR
1.42). These data are compatible with rimonabant’s failure at the
5 mg dose to out-perform placebo treatment in these trials.
The pooled results mask the differential between the findings of
the two trials. STRATUS-EU 2006 consistently failed to demon-
strate the superiority of rimonabant 20 mg over either placebo or
rimonabant 5 mg for prolonged abstinence at either 50 weeks or
at end of treatment (7 to 10 weeks). STRATUS-US 2006 found
statistically significant benefits for the 20 mg regimen for both
comparisons and at both time points. The failure of rimonabant
20mg to establish a significant benefit in the STRATUS-EU 2006
trial can be largely attributed to an exceptionally high placebo
quit rate (19.6% at end of treatment, 14.6% at 50 weeks). This
sustained discrepancy between the trial findings will need to be
explored when more information is made available.
Relapse prevention
It is worth noting that for the phase 1 (cessation) 20 mg quitters in
STRATUS-WW 2005, those randomized to a 5 mg maintenance
dose (ORof 1.51 comparedwith placebo at 52weeks) did at least as
well as those randomized to a 20 mgmaintenance dose (OR 1.49).
This finding is difficult to interpret; considering only the phase 1
20mgquitters, it would suggest that the lower dose ofmaintenance
therapy is as effective as the higher dose, and that both regimens
yield better success rates than placebo treatment. However, for
the phase 1 5 mg quitters, randomized to either a further 5 mg
or to placebo during the maintenance phase, the active treatment
group did no better than the placebo group, suggesting that the
presence or absence of treatment made no difference during the
maintenance phase. Since the quit rates in both phase 1 groups
were similar (31.8% in the 5 mg group versus 33.6% in the 20
mg group), we have no consistent evidence from this trial for
the relative efficacy of the two doses, either for cessation or for
maintenance. We also await information on the phase 3 findings,
which will cover a further 52 weeks without treatment.
Weight change
Among abstinent smokers, we found a statistically significant effect
of rimonabant 20 mg on body weight. Compared with placebo,
rimonabant 20 mg produced significantly less weight gain at end
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of treatment in two trials. Only one of these trials reported the
magnitude of the weight reduction and only for non-obese par-
ticipants. In this study those on rimonabant gained 1.8 kg less
than those on placebo. At 48-week follow-up a pooled analysis of
the two trials showed that there was significantly less weight gain
for rimonabant 20 mg versus placebo, among those maintaining
abstinence. However, a separate analysis for each trial was not pre-
sented. In the trial of relapse prevention, those avoiding relapse
up to 52 weeks gained significantly less weight on rimonabant
20 mg versus placebo, but the magnitude of the weight gain was
not given. Using an intention to treat (ITT) approach, one trial
showed significantly less weight gain for rimonabant 20 mg versus
placebo at end of treatment, and another study showed the same
benefit at 52 weeks follow-up. However, both these analyses were
based on ’last observation carried forward’, which makes interpre-
tation difficult (see comments below). In addition, only one of
these trials presented the weight changes and in this study those on
rimonabant 20 mg gained just 1.4 kg less than those on placebo at
52 weeks. The third trial reported a significant benefit of rimona-
bant 20mg, compared with placebo, on weight gain only for obese
individuals. Overall, the findings suggest that rimonabant 20 mg
may have a modest benefit for moderating weight gain following
smoking cessation both in the short-term and the long-term, but
the magnitude of this benefit is not clear and methodological lim-
itations make interpretation problematic. Without further data it
is not possible to judge the clinical significance of any benefits for
rimonabant on weight gain.
In nearly all cases the magnitude of the weight change was not re-
ported or was reported only for a sub-sample, and in no cases were
95% confidence intervals given. For two trials the key outcome
of weight change among confirmed quitters at the final follow up
was reported using only a pooled analysis combining data from
both studies. None of the studies presented an analysis exclusively
for those who relapsed or continued to smoke. Only one report
examined weight changes according to whether participants were
obese, overweight or of normal weight at baseline. The outcomes
for prolonged smoking cessation were based on the recommended
two-week grace period (Hughes 2003), whereas weight change was
assessed among those who had abstained following a four-week
grace period. It is not clear why this unconventional criterion for
prolonged abstinence was used for weight change.
For the ITT analysis, where there were missing weight data the
last observation was carried forward. This approach makes the
unrealistic assumption that weight remains constant since the last
measurement. Consequently, the results may have been biased in
either direction. For example, if those on placebo dropped out of
the study because they were gaining weight, then carrying the last
observation forward is likely to underestimate their weight gain.
This may then lead to underestimation of the benefit of rimona-
bant compared with placebo. Conversely, if some of those on ri-
monabant withdrew because of weight gain, then carrying their
last observation forward may underestimate the mean weight gain
in this group. The benefit of rimonabant versus placebo would in
that case be overestimated. As the attrition rates were not reported
it is not possible to estimate the extent of this problem. High at-
trition rates would compromise the validity of an ITT analysis.
The obvious solution would be to measure all participants, even
if they did not adhere to the treatment. Another issue related to
drop-outs is that it is possible that some individuals did not take
rimonabant as prescribed but still managed to stop smoking with
little weight gain and attended the follow-up visits. The number
of these individuals is not given, and this may distort the results
in a way that overestimates the benefit of rimonabant for weight
loss.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• From the limited evidence available so far, rimonabant 20 mg
increased about 1½-fold the odds of long-term cessation. The 5
mg dose appeared to confer no significant benefit. However, the
trial findings are at present inconsistent and provisional until
publication of the full reports.
• Adverse events may be dose-related, and may include upper
respiratory tract infection and nausea. The severity and type of
adverse event were inconsistent across the three trials included
in this review. Rates of serious adverse events were reported to
be low.
• Partial study reports, without long-term outcomes at the end of
the no-treatment phase, preclude any clear findings on the use
of rimonabant for maintenance of abstinence.
• Based on the findings of one study, rimonabant 20 mg may
moderate weight gain among those who abstain from smoking
for approximately one year. There is insufficient information
from the other two trials to substantiate this finding. Implica-
tions for future practice will depend upon more detailed pub-
lished reports on the amount of weight gained and attrition
rates.
Implications for research
• The STRATUS smoking cessation findings will need to be
tested through independent population-based trials.
• Rimonabant as an aid to smoking cessation should be directly
compared with other pharmacotherapies, such as nicotine re-
placement therapy, bupropion and varenicline.
• Future researchwill need to consider the benefits of rimonabant
for sub-groups of smokers (e.g. obese versus overweight versus
healthy weight). Rimonabant could also be assessed in relation
to other cessation interventions that influence weight gain (e.g.
nicotine replacement therapy, bupropion, exercise), by direct
comparisons and for interactions with those interventions. We
await publication of detailed peer-reviewed results of the current
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studies before discussing further implications for future research
and practice.
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T A B L E S
Characteristics of included studies
Study STRATUS-EU 2006
Methods SMOKING CESSATION
Country: Belgium, Denmark, France, Spain, Sweden, Switzerland, UK
Setting:
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Characteristics of included studies (Continued )
Study Design: Double-blind placebo-controlled parallel-assignment RCT.
Analysis: Logistic regression on ITT basis.
Participants 783 adults (>=18) smoking at least 10 cpd. Randomized to rimonabant 5mg (N=256), rimonabant 20mg
(N=267), or placebo (N=260).
46%M, 98%W, mean age 42.4, av cpd 22.5, mean yrs smoking 24.9, mean quit attempts 2.9, mean FTND
score 5.6, 35% with a FTND score >7. Mean BMI 25.0.
Interventions (i) Rimonabant 5 mg (ii) Rimonabant 20 mg (iii) Placebo tablets
2-wk pre-treatment screening period, then 10 wks treatment, with TQD at day 15.
Behavioural support:
Treatment phase: Participants were seen weekly for 12 wks (-2 to +10 wks). Brief behavioural counselling
at every visit on tobacco-related topics (e.g. craving, relapse prevention) including diet and exercise, but no
dietary restrictions.
Follow-up phase: clinic visits at wks 11, 14, 22, 30, 39, 48.
Outcomes Primary outcome: Continuous validated abstinence at 7-10 wks. Maximum follow up: 48 wks. Strictest
measure of abstinence: Prolonged validated abstinence from tobacco or nicotine products from wk 2 to wk
48.
Validation method: Expired CO <10ppm at all visits, + cotinine at baseline, wks 8 and 10, and at wks 14,
32 and 50.
Other outcomes: weight change; adverse events.
Notes Identical design to STRATUS-US trial.
Allocation concealment B – Unclear
Study STRATUS-US 2006
Methods SMOKING CESSATION
Country: USA
Setting: Sanofi Clinic, Pennsylvania
Study Design: Double-blind placebo-controlled parallel-assignment RCT.
Analysis: Logistic regression on ITT basis.
Participants 784 adults (>=18) smoking at least 10 cpd. Randomized to rimonabant 5mg (N=262), rimonabant 20mg
(N=261), or placebo (N=261).
51%M, 87%W, mean age 42.3, av cpd 23.6, mean yrs smoking 24.1, mean quit attempts 4.1, mean FTND
score 5.4, 31.7% with a FTND score >7. Mean BMI 27.8.
Interventions (i) Rimonabant 5 mg (ii) Rimonabant 20 mg (iii) Placebo tablets
2-wk pre-treatment screening period, then 10 wks treatment, with TQD at day 15.
Behavioural support:
Treatment phase: Participants were seen weekly for 12 wks (-2 to +10 wks). Brief behavioural counselling
at every visit on tobacco-related topics (e.g. craving, relapse prevention) including diet and exercise, but no
dietary restrictions.
Follow-up phase: clinic visits at wks 11, 14, 22, 30, 39, 48.
Outcomes Primary outcome: Continuous validated abstinence at 7-10 wks. Maximum follow up: 48 wks. Strictest
measure of abstinence: Prolonged validated abstinence from tobacco or nicotine products from wk 2 to wk
48.
Validation method: Expired CO <10ppm at all visits, + cotinine at baseline, wks 8 and 10, and at wks 14,
32 and 50.
Other outcomes: weight change; adverse events.
Notes Identical design to STRATUS-EU trial.
Allocation concealment B – Unclear
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Study STRATUS-WW 2005
Methods RELAPSE PREVENTION TRIAL
Country: Australia, Canada, USA
Study Design: Double-blind placebo-controlled parallel-assignment RCT.
Analysis: Logistic regression on ITT basis.
Participants 5055 adult smokers (>+18) motivated to quit. randomized to rimonabant 5mg (N=2026) or rimonabant
20mg (N=3029).
50% M, 88.8% W, mean age 44.1, av cpd 23.6, mean yrs smoking 24.1, mean quit attempts 4.1, mean
FTND score 5.4, 31.7% with a FTND score >7. Mean BMI 27.8.
Interventions Phase 1: Cessation: Participants randomized to rimonabant 5mg [R5] (N=2026) or rimonabant 20mg [R20]
(N=3029) for 10 wks, with TQD at day 15. Cessation rates at EoT: R5: 644/2026 (31.8%); R20 1017/3029
(33.6%), difference non-significant; Quitters eligible for Phase 2 if: (a) self-reported abstinence for 7+ days,
(b) CO <= 10ppm, and (c) compliance level of 80%+ in last 4 wks of Phase 1.
Phase 2: Relapse prevention: Re-randomized 644 quitters in R5 group to (i) R5 (N=322) or (ii) placebo (N=
322), and 1017 quitters in R20 group to (i) R5 (N=335) or (ii) R20 (N=340) or (iii) placebo (N=342). All
groups received treatment for a further 42 wks.
Behavioural support: Not reported.
Outcomes Primary outcome: Time to relapse for quitters from wks 10 to 32. Relapse defined as >= 7 consecutive days
of smoking (even a puff ), or >= 2 consecutive days with >= 5 cigs (even a puff ) smoked per day.
Long-term follow up: 52 wks, 104 wks.
Secondary outcome: time to relapse for quitters from wks 10 to 52.
Other outcomes: weight change; fasting HDL-cholesterol, triglycerides; safety, adverse events.
Validation: Phase 1: expired CO <10ppm; Phase 2: not reported
Notes Two-year follow-up data awaited.
Allocation concealment B – Unclear
BMI: body mass index (metric measure of weight/height squared)
cpd: cigarettes per day
EoT: end of treatment
FTND: Fagerstrom Test for Nicotine Dependence
ITT: Intention to treat (includes all randomized in original groups)
M: male
TQD: target quit date
W: white
Characteristics of excluded studies
Study Reason for exclusion
STRATUS META 2006 RCT in USA of 530 smokers randomized to rimonabant 20mg or placebo; cessation reported at 10 wks,
EoT, with no long-term follow up.
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A D D I T I O N A L T A B L E S
Table 01. Glossary of terms
Term Definition
Abstinence A period of being quit, i.e. stopping the use of cigarettes or other tobacco products, May
be defined in various ways; see also:
point prevalence abstinence; prolonged abstinence; continuous/sustained abstinence
Biochemical verification Also called ’biochemical validation’ or ’biochemical confirmation’:
A procedure for checking a tobacco user’s report that he or she has not smoked or used
tobacco. It can be measured by testing levels of nicotine or cotinine or other chemicals
in blood, urine, or saliva, or by measuring levels of carbon monoxide in exhaled breath
or in blood.
Bupropion A pharmaceutical drug originally developed as an antidepressant, but now also
licensed for smoking cessation; trade names Zyban, Wellbutrin (when prescribed as an
antidepressant)
Carbon monoxide (CO) A colourless, odourless highly poisonous gas found in tobacco smoke and in the lungs
of people who have recently smoked, or (in smaller amounts) in people who have been
exposed to tobacco smoke. May be used for biochemical verification of abstinence.
Cessation Also called ’quitting’
The goal of treatment to help people achieve abstinence from smoking or other tobacco
use, also used to describe the process of changing the behaviour
Continuous abstinence Also called ’sustained abstinence’
A measure of cessation often used in clinical trials involving avoidance of all tobacco
use since the quit day until the time the assessment is made. The definition occasionally
allows for lapses. This is the most rigorous measure of abstinence
’Cold Turkey’ Quitting abruptly, and/or quitting without behavioural or pharmaceutical support.
Craving A very intense urge or desire [to smoke].
See: Shiffman et al ’Recommendations for the assessment of tobacco craving and
withdrawal in smoking cessation trials’
Nicotine & Tobacco Research 2004: 6(4): 599-614
Dopamine A neurotransmitter in the brain which regulates mood, attention, pleasure, reward,
motivation and movement
Efficacy Also called ’treatment effect’ or ’effect size’:
The difference in outcome between the experimental and control groups
Harm reduction Strategies to reduce harm caused by continued tobacco/nicotine use, such as reducing
the number of cigarettes smoked, or switching to different brands or products, e.g.
potentially reduced exposure products (PREPs), smokeless tobacco.
Lapse/slip Terms sometimes used for a return to tobacco use after a period of abstinence. A lapse
or slip might be defined as a puff or two on a cigarette. This may proceed to relapse, or
abstinence may be regained. Some definitions of continuous, sustained or prolonged
abstinence require complete abstinence, but some allow for a limited number or
duration of slips. People who lapse are very likely to relapse, but some treatments may
have their effect by helping people recover from a lapse.
nAChR [neural nicotinic acetylcholine receptors]: Areas in the brain which are thought to
respond to nicotine, forming the basis of nicotine addiction by stimulating the overflow
of dopamine
Nicotine An alkaloid derived from tobacco, responsible for the psychoactive and addictive effects
of smoking.
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Nicotine Replacement Therapy (NRT) A smoking cessation treatment in which nicotine from tobacco is replaced for a limited
period by pharmaceutical nicotine. This reduces the craving and withdrawal experienced
during the initial period of abstinence while users are learning to be tobacco-free The
nicotine dose can be taken through the skin, using patches, by inhaling a spray, or by
mouth using gum or lozenges.
Outcome Often used to describe the result being measured in trials that is of relevance to the
review. For example smoking cessation is the outcome used in reviews of ways to help
smokers quit. The exact outcome in terms of the definition of abstinence and the length
of time that has elapsed since the quit attempt was made may vary from trial to trial.
Pharmacotherapy A treatment using pharmaceutical drugs, e.g. NRT, bupropion
Point prevalence abstinence (PPA) A measure of cessation based on behaviour at a particular point in time, or during a
relatively brief specified period, e.g. 24 hours, 7 days. It may include a mixture of recent
and long-term quitters. cf. prolonged abstinence, continuous abstinence
Prolonged abstinence A measure of cessation which typically allows a ’grace period’ following the quit date
(usually of about two weeks), to allow for slips/lapses during the first few days when the
effect of treatment may still be emerging.
See: Hughes et al ’Measures of abstinence in clinical trials: issues and recommendations’;
Nicotine & Tobacco Research, 2003: 5 (1); 13-25
Relapse A return to regular smoking after a period of abstinence
Secondhand smoke Also called passive smoking or environmental tobacco smoke [ETS]
A mixture of smoke exhaled by smokers and smoke released from smouldering cigarettes,
cigars, pipes, bidis, etc. The smoke mixture contains gases and particulates, including
nicotine, carcinogens and toxins.
Self-efficacy The belief that one will be able to change one’s behaviour, e.g. to quit smoking
SPC [Summary of Product Characteristics] Advice from the manufacturers of a drug, agreed with the relevant licensing authority,
to enable health professionals to prescribe and use the treatment safely and effectively.
Tapering A gradual decrease in dose at the end of treatment, as an alternative to abruptly stopping
treatment
Titration A technique of dosing at low levels at the beginning of treatment, and gradually
increasing to full dose over a few days, to allow the body to get used to the drug. It is
designed to limit side effects.
Withdrawal A variety of behavioural, affective, cognitive and physiological symptoms, usually
transient, which occur after use of an addictive drug is reduced or stopped.
See: Shiffman et al ’Recommendations for the assessment of tobacco craving and
withdrawal in smoking cessation trials’
Nicotine & Tobacco Research 2004: 6(4): 599-614
A N A L Y S E S
Comparison 01. Rimonabant 20mg vs placebo
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Prolonged abstinence at wk 50 2 1049 Odds Ratio (Fixed) 95% CI 1.61 [1.12, 2.30]
02 Continuous 4-wk abstinence at
EOT (wks 7-10)
2 1049 Odds Ratio (Fixed) 95% CI 1.63 [1.21, 2.19]
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Comparison 02. Relapse prevention
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 rimonabant 20mg vs placebo at
52 weeks
1 682 Odds Ratio (Fixed) 95% CI 1.49 [1.09, 2.04]
02 rimonabant 5mg vs placebo at
52 weeks
1 677 Odds Ratio (Fixed) 95% CI 1.51 [1.11, 2.07]
Comparison 03. Rimonabant 5mg vs placebo
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Prolonged abstinence at wk 50 2 1039 Odds Ratio (Fixed) 95% CI 1.13 [0.77, 1.66]
02 Continuous 4-wk abstinence at
EOT (wks 7-10)
2 1039 Odds Ratio (Fixed) 95% CI 1.15 [0.84, 1.56]
Comparison 04. Rimonabant 20mg vs rimonabant 5mg
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Prolonged abstinence at wk 50 2 1046 Odds Ratio (Fixed) 95% CI 1.42 [1.00, 2.02]
02 Continuous 4-wk abstinence at
EOT (wks 7-10)
2 1046 Odds Ratio (Fixed) 95% CI 1.42 [1.06, 1.90]
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G R A P H S A N D O T H E R T A B L E S
Analysis 01.01. Comparison 01 Rimonabant 20mg vs placebo, Outcome 01 Prolonged abstinence at wk 50
Review: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
Comparison: 01 Rimonabant 20mg vs placebo
Outcome: 01 Prolonged abstinence at wk 50
Study rimonabant placebo Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
STRATUS-US 2006 38/261 19/261 34.1 2.17 [ 1.22, 3.88 ]
STRATUS-EU 2006 49/267 38/260 65.9 1.31 [ 0.83, 2.09 ]
Total (95% CI) 528 521 100.0 1.61 [ 1.12, 2.30 ]
Total events: 87 (rimonabant), 57 (placebo)
Test for heterogeneity chi-square=1.76 df=1 p=0.18 I² =43.2%
Test for overall effect z=2.58 p=0.01
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
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Analysis 01.02. Comparison 01 Rimonabant 20mg vs placebo, Outcome 02 Continuous 4-wk abstinence at
EOT (wks 7-10)
Review: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
Comparison: 01 Rimonabant 20mg vs placebo
Outcome: 02 Continuous 4-wk abstinence at EOT (wks 7-10)
Study rimonabant placebo Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
STRATUS-EU 2006 66/267 51/260 56.1 1.35 [ 0.89, 2.03 ]
STRATUS-US 2006 72/261 42/261 43.9 1.99 [ 1.30, 3.05 ]
Total (95% CI) 528 521 100.0 1.63 [ 1.21, 2.19 ]
Total events: 138 (rimonabant), 93 (placebo)
Test for heterogeneity chi-square=1.65 df=1 p=0.20 I² =39.3%
Test for overall effect z=3.22 p=0.001
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
Analysis 02.01. Comparison 02 Relapse prevention, Outcome 01 rimonabant 20mg vs placebo at 52 weeks
Review: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
Comparison: 02 Relapse prevention
Outcome: 01 rimonabant 20mg vs placebo at 52 weeks
Study rimonabant placebo Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
STRATUS-WW 2005 141/340 110/342 100.0 1.49 [ 1.09, 2.04 ]
Total (95% CI) 340 342 100.0 1.49 [ 1.09, 2.04 ]
Total events: 141 (rimonabant), 110 (placebo)
Test for heterogeneity: not applicable
Test for overall effect z=2.51 p=0.01
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
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Analysis 02.02. Comparison 02 Relapse prevention, Outcome 02 rimonabant 5mg vs placebo at 52 weeks
Review: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
Comparison: 02 Relapse prevention
Outcome: 02 rimonabant 5mg vs placebo at 52 weeks
Study rimonabant placebo Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
STRATUS-WW 2005 140/335 110/342 100.0 1.51 [ 1.11, 2.07 ]
Total (95% CI) 335 342 100.0 1.51 [ 1.11, 2.07 ]
Total events: 140 (rimonabant), 110 (placebo)
Test for heterogeneity: not applicable
Test for overall effect z=2.59 p=0.01
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
Analysis 03.01. Comparison 03 Rimonabant 5mg vs placebo, Outcome 01 Prolonged abstinence at wk 50
Review: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
Comparison: 03 Rimonabant 5mg vs placebo
Outcome: 01 Prolonged abstinence at wk 50
Study rimonabant placebo Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
STRATUS-EU 2006 43/256 38/260 64.1 1.18 [ 0.73, 1.90 ]
STRATUS-US 2006 20/262 19/261 35.9 1.05 [ 0.55, 2.02 ]
Total (95% CI) 518 521 100.0 1.13 [ 0.77, 1.66 ]
Total events: 63 (rimonabant), 57 (placebo)
Test for heterogeneity chi-square=0.08 df=1 p=0.78 I² =0.0%
Test for overall effect z=0.64 p=0.5
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
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Analysis 03.02. Comparison 03 Rimonabant 5mg vs placebo, Outcome 02 Continuous 4-wk abstinence at
EOT (wks 7-10)
Review: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
Comparison: 03 Rimonabant 5mg vs placebo
Outcome: 02 Continuous 4-wk abstinence at EOT (wks 7-10)
Study rimonabant placebo Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
STRATUS-EU 2006 62/256 51/260 51.9 1.31 [ 0.86, 1.99 ]
STRATUS-US 2006 41/262 42/261 48.1 0.97 [ 0.61, 1.55 ]
Total (95% CI) 518 521 100.0 1.15 [ 0.84, 1.56 ]
Total events: 103 (rimonabant), 93 (placebo)
Test for heterogeneity chi-square=0.89 df=1 p=0.35 I² =0.0%
Test for overall effect z=0.85 p=0.4
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
Analysis 04.01. Comparison 04 Rimonabant 20mg vs rimonabant 5mg, Outcome 01 Prolonged abstinence at
wk 50
Review: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
Comparison: 04 Rimonabant 20mg vs rimonabant 5mg
Outcome: 01 Prolonged abstinence at wk 50
Study rimonabant 20 rimonabant 5 Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
STRATUS-EU 2006 49/267 43/256 67.8 1.11 [ 0.71, 1.75 ]
STRATUS-US 2006 38/261 20/262 32.2 2.06 [ 1.16, 3.65 ]
Total (95% CI) 528 518 100.0 1.42 [ 1.00, 2.02 ]
Total events: 87 (rimonabant 20), 63 (rimonabant 5)
Test for heterogeneity chi-square=2.76 df=1 p=0.10 I² =63.7%
Test for overall effect z=1.96 p=0.05
0.1 0.2 0.5 1 2 5 10
Favours R5 Favours R 20
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Analysis 04.02. Comparison 04 Rimonabant 20mg vs rimonabant 5mg, Outcome 02 Continuous 4-wk
abstinence at EOT (wks 7-10)
Review: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
Comparison: 04 Rimonabant 20mg vs rimonabant 5mg
Outcome: 02 Continuous 4-wk abstinence at EOT (wks 7-10)
Study rimonabant 20 rimonabant 5 Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
STRATUS-EU 2006 66/267 62/256 61.7 1.03 [ 0.69, 1.53 ]
STRATUS-US 2006 72/261 41/262 38.3 2.05 [ 1.34, 3.16 ]
Total (95% CI) 528 518 100.0 1.42 [ 1.06, 1.90 ]
Total events: 138 (rimonabant 20), 103 (rimonabant 5)
Test for heterogeneity chi-square=5.36 df=1 p=0.02 I² =81.3%
Test for overall effect z=2.38 p=0.02
0.1 0.2 0.5 1 2 5 10
Favours R5 Favours R20
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